FS.3.2.0002.15 Human blood coagulation factor VII. Medicinal reference book geotar

Factor VII of blood clotting, or, as it is also called - proconvertin, is formed in the liver and depends on the presence of vitamin K in the body. Factor VII activates factor X of blood clotting. The active form of factor VII is formed after vascular injury when factor VII binds to factor III. This is one of the main reactions that ensure blood clotting. In addition to factor III, factor VII can also be activated by coagulation factors XIIa, IXa, Xa and IIa.

Genetic mutations in factor VII can lead to decreased blood clotting and reduced thrombus formation. For example, this happens if guanine is replaced at position 10976 by adenine, causing the amino acid arginine to give way to glutamine.

The norm of factor VII in the blood. Result interpretation (table)

A factor VII blood test is done to assess the likelihood of a patient having a myocardial infarction and to understand possible reasons spontaneous abortion.

Blood is taken from a vein, in the morning, on an empty stomach.

The norm of factor VII in the blood ordinary people and pregnant women:

If factor VII is elevated, what does it mean?

No data.

If factor VII is low, what does it mean?

Factor VII deficiency may be hereditary. This disease was first described in 1951. Bleeding from small vessels are found, as a rule, immediately after the birth of a child, they look like small hematomas, the development of gastric or umbilical bleeding. But even if this is not immediately noticed, congenital factor VII deficiency will definitely manifest itself in the first two years of a child's life. Bleeding from any injury or surgical interventions become especially strong, in women, congenital factor VII deficiency manifests itself in the form of extremely heavy monthly bleeding. The likelihood of developing a hemorrhagic stroke is extremely high due to the danger of cerebral hemorrhage.

The disease generally resembles hemophilia. With it, the risk of hemorrhages in the joints also remains, but they do not happen so often and do not lead to the development of osteoarthritis.

The disease may be mild, moderate or severe degree. At mild degree hemorrhages from the vessels may not appear at all, and reduced blood clotting manifests itself only during injuries and operations.

Acquired hypoproconvetremia (this is what this pathology is called) is usually caused by liver diseases or after treatment indirect anticoagulants. Reduced rate factor VII in the blood, usually seen with the following diseases:

• viral hepatitis,
• spicy alcoholic hepatitis,
• cirrhosis of the liver,
• chronic persistent hepatitis.

Monitoring the activity of factor VII can monitor the onset of liver failure.

The marker is associated with a change in the structure of factor VII of the blood coagulation system. It is being studied to identify genetic resistance to myocardial infarction, the risk of developing thromboembolic complications.

The name of the geneF7

OMIM*613878

Localization of a gene on a chromosome– 13q34

Gene function

Gene F7 encodes coagulation factor VII (proconvertin), a protein synthesized in the liver and regulating blood coagulation, acting as an activator of coagulation factors X (F10) and IX (F9) in the presence of vitamin K.

genetic markerF7 G10976A

The DNA region of the F7 gene, in which guanine (G) is replaced by adenine (A) at position 10976, is designated as a genetic marker F7 G10976A. Consequently, the biochemical properties of the enzyme, in which the amino acid arginine is replaced by glutamine, also change.

G10976A - substitution of guanine (G) for adenine (A) at position 10976 of the DNA sequence encoding the F7 protein.

Arg353Gln is the substitution of the amino acid arginine for glutamine in the amino acid sequence of the F7 protein.

Possible genotypes

Frequency of occurrence in the population

The frequency of allele A in the European population is 10%.

Association of the marker with diseases

• Thromboembolism
• myocardial infarction

Description

The hemostasis system is a set of biochemical processes that provide liquid state blood, maintaining its normal rheological properties(viscosity), preventing and stopping bleeding. It includes factors of coagulation, natural anticoagulant and fibrinolytic blood systems. Normally, the processes in it are balanced, which ensures the liquid state of the blood. Displacement of this equilibrium due to internal or external factors may increase the risk of bleeding and thrombosis.

Gene F7 encodes blood coagulation factor VII (proconvertin, F7), a vitamin K-dependent proenzyme produced in the liver. Basic physiological role F7 is the activation of clotting factor X (F10). After vessel injury, F7 binds to tissue factor III (TFA) and becomes active form. This reaction is the main event in the process of blood clotting. The complex of TFA and F7 serves to activate factor IX (F9), X (F10) and factor VII (F7). Activated factor X (Xa), in turn, is involved in the activation of prothrombin and its transition to thrombin. Factor VII can also be activated by factors XIIa, IXa, Xa and IIa.

Changes in the gene F7 in most cases, they have a protective effect on the risk of thromboembolism. Replacement of guanine (G) with adenine (A) at position 10976 (genetic marker G10976A) leads to a change biochemical properties factor VII, in which the amino acid arginine is replaced by glutamine. The decrease in F7 activity as a result of the replacement helps to reduce thrombus formation. The A/A genotype is responsible for a 72% decrease in F7 enzyme activity compared to the wild type (G/G genotype).

The marker is associated with a reduced likelihood of myocardial infarction, even in the presence of angiographically documented, severe coronary atherosclerosis. Heterozygotes (carriers of one A and one G allele, A/G genotype) have a 2-fold lower risk of myocardial infarction than carriers of two G alleles (G/G genotype).

Interpretation of results

Genotype assessment by marker:

• G/G - normal activity of the F7 protein
• G/A - F7 protein activity is moderately reduced
• A / A - the activity of the F7 protein is significantly reduced

The interpretation of the results of the study should be carried out by a doctor in combination with other genetic, anamnestic, clinical and laboratory data.

Important Notes

For this marker, there is no concept of "norm" and "pathology", since the gene polymorphism is being studied.

Filterable List

Active substance:

Instructions for medical use

Factor VII (Blood Clotting Factor VII)
Instructions for medical use- RU No. P N016158/01

Last Modified Date: 10.05.2016

Dosage form

Lyophilizate for solution for intravenous administration

Compound

Composition (for 1 bottle):

Active ingredient:

Factor VII 600 ME

As plasma protein 50-200 mg/vial

Auxiliary ingredients:

Sodium citrate dihydrate 40 mg

Sodium chloride 80 mg

Heparin sodium 250 ME

Solvent:

Water for injections 10 ml

Description of the dosage form

Lyophilisate: white or slightly colored powder or friable solid mass.

Solvent: clear, colorless liquid.

Reconstituted solution: clear to slightly opalescent, colorless to yellowish color solution.

Pharmacological group

Hemostatic agent

Pharmacodynamics

Factor VII is one of the vitamin K-dependent factors in normal human plasma, a component of the extrinsic pathway of the blood coagulation system. It is a single chain glycoprotein with molecular weight about 50,000 daltons. Factor VII is a zymogen for factor Vila serine protease (an active serine protease) that triggers outer path blood coagulation systems. The tissue factor-factor VIIa complex activates coagulation factors IX and X, resulting in the formation of factors IXa and Xa. With further deployment of the coagulation cascade, thrombin is formed, fibrinogen is converted to fibrin, and a clot is formed. Normal thrombin formation is also extremely important for platelet function as part of the hemostasis system. Hereditary factor VII deficiency is an autosomal recessive disorder. The use of human factor VII provides an increase in plasma concentration of factor VII and can temporarily eliminate the defect in blood coagulation in patients with factor VII deficiency.

Pharmacokinetics

With intravenous administration of factor VII, its concentration in the patient's blood plasma rises to 60-100%.

The half-life is about 3-5 hours.

Indications

The drug Factor VII is indicated:

• in the treatment of blood clotting disorders caused by isolated hereditary factor VII deficiency;
• for the prevention of blood clotting disorders caused by isolated hereditary factor VII deficiency, with a history of bleeding and a residual concentration of factor VII below 25% (0.25 IU / ml).

The drug does not contain significant amounts of factor VIIa and should not be used in patients with hemophilia with inhibitors.

Contraindications

• hypersensitivity to active substance or any component of the drug;
• high risk of thrombosis or disseminated intravascular coagulation (DIC);
• a known allergy to heparin or a history of heparin-induced thrombocytopenia;
• children under 6 years of age (currently available data are insufficient to recommend the use medicinal product Factor VII in children under 6 years of age).

Use during pregnancy and lactation

The effect of Factor VII on fertility has not been studied in controlled clinical trials.

Safety human factor coagulation VII when used during pregnancy has not been confirmed by controlled clinical studies.

Data obtained in animal experiments do not allow to evaluate the safety of the drug for pregnant women, the effect on the development of the embryo and fetus, childbirth or postnatal development. The physician must carefully evaluate the expected benefit and possible risk and prescribe Factor VII during pregnancy and during breastfeeding only under strict guidelines.

See section " special instructions”, which contains information about the risks associated with potential danger infection of pregnant women with parvovirus B19.

Dosage and administration

Treatment with Factor VII should only be carried out by a physician experienced in the use of replacement therapy clotting factors.

Factor VII is administered intravenously as intermittent injections or infusions.

Reconstitution of the Factor VII preparation should be carried out immediately before use. When used as an infusion, only the supplied infusion set should be used.

Recovery of lyophilisate

1. Warm an unopened vial of solvent to room temperature, but not more than up to 37°С.

2. Remove the protective discs from the lyophilisate and solvent vials (Fig. A) and wipe the stoppers of both vials.

3. Remove, by rotating and removing, the protective cover from one end of the supplied transfer needle (Fig. B). Insert an open needle through the rubber stopper into the diluent vial (Figure B).

4. Remove the protective coating from the other end of the transfer needle without touching the surface of the needle.

5. Invert the solvent vial vertically over the concentrate vial and insert the free end of the transfer needle through the rubber stopper of the concentrate vial (Fig. D). The solvent will enter the concentrate vial under vacuum.

6. Separate the two vials by removing the needle from the stopper of the concentrate vial (Fig. E). Gently shake and swirl the concentrate vial to promote dissolution.

7. After reconstitution is complete, insert the supplied aeration needle (Fig. E) and allow the foam to settle completely. Remove the aeration needle.

8. Prior to administration, the resulting concentrate should be carefully examined for the presence of foreign particles and discoloration (the concentrate may be colorless or have a yellowish color).

In case of detection of foreign particles, discoloration or turbidity, the drug should not be administered!

The drug must be used immediately after recovery.

Method of administration

1. Remove, by rotating and removing, the protective cover from one end of the supplied filter needle, and place it on a sterile disposable syringe. Draw the solution into the syringe (Fig. G).

2. Disconnect the filter needle from the syringe and perform a slow intravenous administration solution using a transfusion system (or the included disposable needle).

Do not exceed the infusion rate of 2 ml/min!

Doses and duration of replacement therapy depend on the severity of factor VII deficiency, location and severity of bleeding episodes, and clinical condition sick. The association between factor VII residual levels and bleeding tendency is less clear in some patients than in classical hemophilia.

The number of Factor VII units administered is expressed in International Units (IU) according to the current WHO standard for Factor VII preparations. Plasma Factor VII activity is expressed either as a percentage (relative to normal plasma) or in International Units (relative to International Standard factor VII plasma).

One International Unit (IU) of factor VII activity is equivalent to the amount of factor VII activity in 1 ml of normal human plasma.

Based on the empirical observation that 1 International Unit (IU) of factor VII per kilogram of body weight increases plasma factor VII activity by approximately 1.9% (0.019 IU/mL) relative to normal level activity.

The required dose is determined using the following formula:

Required dose (ME) = body weight (kg) × desired increase in factor VII activity (IU/mL) × 53* (unit divided by observed recovery (mL/kg))

*(because 1: 0.019 = 52.6)

In each individual case, the amount of the drug to be administered and the frequency of application should always be correlated with clinical efficacy. This is particularly important in the treatment of factor VII deficiency, since an individual's tendency to bleed does not depend strictly on plasma factor VII activity as measured by laboratory tests. Individual dosage recommendations for Factor VII should be based on regular measurements of factor VII plasma concentrations and ongoing monitoring of the patient's clinical condition. The intervals between doses should take into account the short half-life of factor VII from the circulatory bed, which is from 3 to 5 hours.

When using the drug Factor VII in the form of intermittent injections / infusions, it is advisable to do the intervals between doses from 6 to 8 hours. In general, the treatment of factor VII deficiency requires (depending on activity in normal plasma) lower doses of the deficient factor compared to classical hemophilia (hemophilia A and B). The table below shows exemplary recommendations on the use of intermittent injections/infusions based on the limited clinical experience available.

* 1 IU/mL=100 IU/dL=100% normal plasma. Plasma factor VII activity is expressed either as a percentage (relative to the content in normal plasma, taken as 100%), or in International Units (relative to international standard for factor VII in plasma).

** Based clinical assessment in each case, provided that adequate hemostasis is achieved towards the end of treatment, lower doses may be sufficient. The intervals between doses should be selected taking into account short period the elimination half-life of factor VII from the circulatory bed, which is approximately 3 to 5 hours. Support if necessary high concentrations factor VII over a long period of time doses should be administered at intervals of 8-12 hours.

Unused drug and waste material must be disposed of in accordance with local requirements.

Side effects

Adverse Effects Observed in Clinical Studies

Adverse reactions encountered during the course of clinical research, are listed according to the following gradation: according to the following gradation: very often (> 1/10); often (> 1/100<1/10); нечасто (>1/1000<1/100); редко (> 1/10 000<1/1000); очень редко (<1/10 000, включая единичные сообщения).

The table below summarizes the adverse reactions reported in a clinical study of 57 adult and pediatric patients with hereditary factor VII deficiency who were treated with Factor VII for acute bleeding control, during surgery, and for long-term bleeding prevention. In this study, Factor VII was administered for 8234 days.

a - Rate per Patient was determined based on the number of patients who experienced this adverse event, assessed by the investigator as at least possibly related to the administration of the drug, and assessed in the same way by Baxter Healthcare Corporation.

b = "Frequency per day of administration" was determined based on the total number of observations of this adverse event, assessed by the investigator as at least possibly related to the administration of the drug, and thus estimated by Baxter Healthcare Corporation.

c - "Violation of well-being" - the applied term, implying a fuzzy perception.

Undesirable effects observed during post-registration use

The following adverse effects have been reported in post-marketing experience, listed according to the MedDRA Organ System Classification in ascending order of severity, where applicable.

Blood and lymphatic system disorders: factor VII* inhibition.

*-Coded under the preferred MedDRA term for the presence of anti-factor VII antibodies.

Immune system disorders: hypersensitivity reactions.

Mental disorders: confusion, insomnia, restlessness.

Nervous system disorders: cerebral vein thrombosis, dizziness, sensory disturbance, headache.

Cardiovascular disorders: arrhythmia, hypotension, deep vein thrombosis, superficial vein thrombosis, facial flushing.

Respiratory, thoracic and mediastinal disorders: bronchospasm, shortness of breath.

Gastrointestinal disorders: diarrhea, nausea.

Skin and subcutaneous tissue disorders: itching.

General disorders and reactions at the injection site: chest discomfort.

Class-Specific Reactions

When using factor VII preparations and prothrombin complex preparations containing factor VII, the following adverse events were noted: stroke, myocardial infarction, arterial thrombosis, pulmonary embolism, disseminated intravascular coagulation, allergic or anaphylactic reactions, urticaria, vomiting, fever.

Precautionary measures

When conducting coagulation tests sensitive to heparin in patients receiving high doses of Factor VII, the presence of heparin in the preparation should be taken into account.

special instructions

When using preparations containing factor VII, the development of hypersensitivity reactions, including anaphylactic reactions, was noted. Patients and their loved ones should be informed about the early signs of hypersensitivity reactions. If such symptoms occur, patients should be advised to immediately discontinue the use of the drug and contact their doctor.

If allergic and / or anaphylactic reactions occur, the administration should be stopped immediately. In case of shock, standard medical measures should be taken.

Standard measures for the prevention of infections resulting from the use of medicinal products derived from human blood or plasma include the selection of donors, the screening of material donated by individual donors and plasma pools for specific markers of infection, and the introduction of effective virus inactivation/removal steps into production . Despite this, when using medicinal products prepared from human blood or plasma, the risk of transmission of infectious diseases, including those caused by unknown viruses or other pathogens, cannot be completely excluded.

Applied technologies for the removal and inactivation of pathogens may be of limited effectiveness against some non-enveloped viruses, in particular, parvovirus B19. Infection with parvovirus B19 can be dangerous for pregnant women (infection of the fetus) and patients with immunodeficiency or increased breakdown of red blood cells (in particular, with hemolytic anemia).

Appropriate vaccination (against hepatitis A and B) may be recommended for patients who are regularly treated with plasma-derived Factor VII.

Each time Factor VII is administered, it is strongly recommended that the name and batch number of the drug be recorded so that the relationship between the administration of the drug and the patient's condition can be traced.

During therapy with drugs containing factor VII, there is a risk of developing thromboembolic complications and DIC. Thrombosis, including deep vein thrombosis, and thrombophlebitis have been observed during treatment with Factor VII. Patients receiving Factor VII therapy should be closely monitored due to the possibility of developing signs and symptoms of thromboembolic complications and DIC.

Due to the risk of thromboembolic complications and DIC, particularly rigorous monitoring should be performed when administering human factor VII to patients with coronary heart disease, liver disease, prior to surgery, neonatal neonates, or other patients.

Replacement therapy with human factor VII can lead to the formation of circulating antibodies that inhibit factor VII. If such inhibitors appear, this condition manifests itself as an insufficient clinical response.

Influence on the ability to drive vehicles and other mechanisms

There is no information on the effect of Factor VII on the ability to drive a car and use complex machinery that requires increased attention.

Release form

Lyophilisate for solution for intravenous administration 600 ME

600 IU of the drug in a glass vial (type II, EP) and 10 ml of solvent in a glass vial (type I, EP) in a carton box together with a set for dissolution and administration (disposable syringe, disposable needle, transfer needle, filter needle , aeration needle, transfusion system) and instructions for use

Storage conditions

At temperatures from 2 to 8°C.

Keep out of the reach of children.

Best before date

Do not use after the expiry date stated on the packaging.

Terms of dispensing from pharmacies

By prescription.

Factor VII (Blood coagulation factor VII) - instructions for medical use - RU No. P N016158 / 01 dated 2009-12-15

Synonyms of nosological groups

lyophilisate for preparation. r-ra d / in / in the introduction of 600 IU: fl. 1 PC. in set with solvent, syringe, disposable needle, transfer needle, filtering needle, aeration needle. and transfusion system Reg. No.: P N016158/01

Clinico-pharmacological group:

Blood coagulation factor VII preparation

Release form, composition and packaging

Lyophilisate for solution for intravenous administration white or slightly colored, in the form of powder or friable solid mass.

Excipients: sodium citrate dihydrate, sodium chloride, heparin.

Solvent: water d / i - 10 ml.

Vials (1) complete with a solvent (vial), a disposable syringe, a disposable needle, a transfer needle, a filtering needle, an aeration needle and a transfusion system - packs of cardboard.

Description of the active ingredients of the drug Factor vii (clotting factor vii)»

pharmachologic effect

Factor VII is one of the vitamin K-dependent factors in normal human plasma, a component of the external pathway of the blood coagulation system. It is a zymogen for the factor VIla serine protease, which triggers the extrinsic pathway of the blood coagulation system. The administration of human factor VII concentrate increases the plasma concentration of factor VII and provides a temporary correction of the defect in the blood coagulation system in patients with factor VII deficiency.

Indications

Treatment and prevention of blood clotting disorders caused by hereditary or acquired factor VII deficiency;

- acute bleeding and prevention of bleeding during surgical interventions in patients with congenital factor VII deficiency (hypo- or aproconvertinemia);

- acute bleeding and prevention of bleeding during surgical interventions with acquired factor VII deficiency due to oral anticoagulants;

- deficiency of vitamin K (for example, in violation of its absorption in the gastrointestinal tract, with prolonged parenteral nutrition);

- liver failure (for example, with hepatitis, cirrhosis of the liver, severe toxic liver damage).

Dosing regimen

The duration of replacement therapy and dose depend on the severity of factor VII deficiency, the location and extent of bleeding or hemorrhage, and the clinical condition of the patient. The prescribed dose of factor VII is calculated in international units (IU) according to current WHO standards for preparations containing factor VII. Plasma factor VII activity can be calculated as a percentage of normal and in international units.

One International Unit of Factor VII activity is equivalent to 1 ml of Factor VII activity in normal human plasma.

The required dose is calculated on the basis of empirical observation, which showed that with the introduction of 1 ME of factor VII per 1 kg of body weight, the activity of factor VII in plasma increases by 1.7%.

The calculation of the required dose is carried out according to the following formula:

Required dose (ME) = body weight (kg) x desired increase in factor VII activity (%) x 0.6

When determining the dose and frequency of administration of the drug in each case, the clinical effect should be taken into account.

When choosing the interval of administration, it should be taken into account that the half-life of factor VII is very short - approximately 3-5 hours.

If it is necessary to maintain a high level of factor VII in plasma for a long time, the drug should be administered at intervals of 8-12 hours.

Dose adjustment in liver disease is not required.

Method of administration

A solution for IV administration from Factor VII lyophilisate should be prepared immediately prior to administration. Use only the supplied insertion kit. The solution should be clear or slightly opalescent. Do not use the solution if it is cloudy or contains particulate matter. All used materials and unused solution must be disposed of in accordance with established regulations.

Preparation of a solution from a lyophilized concentrate

1. Warm the closed solvent bottle to room temperature (not higher than 37°C).

2. Remove the protective caps from the Factor VII Concentrate and Diluent vials and disinfect the rubber stoppers on both vials.

3. Turn and then remove the protective packaging from one end of the adapter needle included in the kit. Use the end of the needle to pierce the rubber stopper of the solvent bottle.

4. Carefully remove the protective packaging from the other end of the adapter needle without touching the needle itself.

5. Invert the solvent vial and pierce the rubber stopper of the Factor VII concentrate vial with the free end of the adapter needle. The vacuum will force the solvent into the Factor VII Concentrate vial.

6. Disconnect the vials by removing the adapter needle from the Factor VII concentrate vial. For faster dissolution of the concentrate, the bottle is gently rotated and shaken.

7. For foam deposition after complete dissolution of the concentrate, insert the supplied air needle into the vial. Remove the airway needle after the foam has settled.

In/in jet injection

1. Turn and then remove the protective packaging from the filter needle and put it on a sterile disposable syringe. Draw the solution into a syringe.

2. Disconnect the filter needle from the syringe, put on a butterfly needle or a disposable injection needle and inject the intravenous solution slowly (at a rate of no more than 2 ml / min).

3. When administered at home, the patient must place all used materials in the package from the drug and hand over to a medical institution where he is observed for control.

IV drip

For intravenous drip, a disposable transfusion system with a filter should be used.

Side effect

Rarely there is the development of allergic reactions (such as urticaria, nausea, vomiting, bronchospasm, lowering blood pressure), in some cases - severe anaphylaxis (including shock).

In rare cases fever was noted. When treated with prothrombin complex factors, one of which is factor VII, thromboembolic complications are possible, especially in cases where high doses of the drug are prescribed and / or in patients with risk factors for thromboembolism.

Contraindications

- syndrome of disseminated intravascular coagulation (DIC) and / or hyperfibrinolysis until the underlying causes are eliminated;

- a history of heparin-induced thrombocytopenia;

- age up to 6 years;

- hypersensitivity to the drug or to any of its components.

Due to the risk of developing thromboembolic complications, the drug with special care should be used in patients with a history of coronary artery disease, myocardial infarction, liver disease, as well as in patients in the postoperative period, newborns and those at high risk of developing thromboembolism or DIC. In these cases, it is necessary to correlate the possible benefits of using Factor VII with the risk of developing these complications.

Pregnancy and lactation

The safety of Factor VII during pregnancy has not been confirmed by controlled clinical trials. Therefore, Factor VII can be administered during pregnancy and lactation only under strict indications.

Application for violations of liver function

With caution, the drug should be prescribed for liver diseases.

Application for children

Contraindicated in children under 6 years of age.

special instructions

Since Factor VII is a protein drug, allergic reactions may occur. Patients should be informed about the early symptoms of allergy, such as urticaria (including generalized), chest tightness, wheezing, drop in blood pressure and anaphylaxis. If these symptoms appear, patients should immediately stop treatment and contact their doctor.

When shock develops, one should act in accordance with the currently established rules for the treatment of shock.

Based on the experience with the human plasma prothrombin complex, we can talk about an increased risk of thromboembolic complications and DIC in patients receiving human plasma factor VII.

Theoretically, factor VII replacement therapy could lead to the development of factor VII inhibitors in the patient. However, to date, no such case has been described in clinical practice.

The amount of sodium in the maximum daily dose may exceed 200 mg, which should be considered when used in patients on a low sodium diet.

Factor VII is made from human plasma. With the introduction of drugs made from human blood or plasma, the possibility of transmission of viruses cannot be completely excluded. This also applies to pathogens whose nature is currently unknown.

The risk of virus transmission is minimized as a result of the implementation of a number of security measures, namely:

- selection of donors based on data from a medical examination and screening of blood and plasma of each donor, as well as plasma pools for HBsAg and antibodies to HIV and hepatitis C viruses;

- testing of plasma pools for the presence of genomic material of hepatitis A, B and C, HIV-1 and HIV-2 viruses, as well as parvovirus B19;

— application of virus inactivation/removal methods in the manufacturing process. The effectiveness of these methods against hepatitis A, B and C, HIV-1 and HIV-2 viruses has been established on pathogen viruses and/or model viruses.

However, the effectiveness of the applied methods of inactivation/removal of viruses may be insufficient against some non-enveloped viruses, for example, parvovirus B19, as well as against currently unknown viruses. Infection with parvovirus B19 can be dangerous for pregnant women (infection of the fetus), as well as for people with immunodeficiency or increased production of red blood cells (for example, with hemolytic anemia).

Hepatitis A and B vaccination is recommended for patients receiving human plasma factor VII.

There are currently insufficient data to recommend the use of Factor VII in children under 6 years of age.

Influence on the ability to drive vehicles and control mechanisms

There was no effect on the ability to drive a car and moving mechanisms.

Overdose

When using large doses of drugs containing factor VII, there have been cases of myocardial infarction, disseminated intravascular coagulation, venous thrombosis and pulmonary embolism. Therefore, in the event of an overdose in patients with risk factors for thromboembolic complications or disseminated intravascular coagulation, the likelihood of developing these complications increases.

drug interaction

Terms of dispensing from pharmacies

The drug is dispensed by prescription.

Terms and conditions of storage

The drug should be stored out of the reach of children at a temperature of 2 ° to 8 ° C. Shelf life - 3 years.

drug interaction

INTERACTIONS WITH OTHER DRUGS

No interactions of human plasma Factor VII with other drugs have been noted.

Prior to administration, Factor VII should not be mixed with other drugs. When using a venous catheter, it is recommended to flush it with isotonic saline before and after the administration of Factor VII.

Impact on laboratory parameters:

In patients receiving high doses of Factor VII, when conducting coagulation tests that are sensitive to heparin, the presence of heparin in the preparation should be taken into account. If necessary, the effect of heparin can be neutralized by adding protamine to the test sample.

It is carried out mainly by proteins called plasma coagulation factors. Plasma coagulation factors are procoagulants whose activation and interaction lead to the formation of a fibrin clot.

According to the International Nomenclature, plasma coagulation factors are indicated by Roman numerals, with the exception of von Willebrand, Fletcher and Fitzgerald factors. To indicate the activated factor, the letter "a" is added to these numbers. In addition to the numerical designation, other names of clotting factors are also used - according to their function (for example, factor VIII - antihemophilic globulin), by the names of patients with a newly discovered deficiency of one or another factor (factor XII - Hageman factor, factor X - Stuart-Prauer factor) , less often - by the names of the authors (for example, the von Willebrand factor).

Below are the main blood coagulation factors and their synonyms according to the international nomenclature and their main properties in accordance with the literature and special studies.

Fibrinogen (factor I)

Fibrinogen is synthesized in the liver and cells of the reticuloendothelial system (in the bone marrow, spleen, lymph nodes, etc.). In the lungs, under the action of a special enzyme - fibrinogenase or fibrinodestructase - fibrinogen is destroyed. The content of fibrinogen in plasma is 2 - 4 g / l, the half-life is 72 - 120 hours. The minimum level required for hemostasis is 0.8 g/L.

Under the influence of thrombin, fibrinogen is converted into fibrin, which forms a mesh basis of a thrombus that clogs a damaged vessel.

Prothrombin (factor II)

Prothrombin is synthesized in the liver with the participation of vitamin K. The content of prothrombin in plasma is about 0.1 g / l, the half-life is 48 - 96 hours.

The level of prothrombin, or its functional usefulness, decreases with endogenous or exogenous vitamin K deficiency, when defective prothrombin is formed. The rate of blood clotting is disturbed only when the concentration of prothrombin is below 40% of the norm.

Under natural conditions, during blood coagulation under the action of and, as well as with the participation of factors V and Xa (activated factor X), united by the general term "prothrombinase", prothrombin turns into thrombin. The process of converting prothrombin to thrombin is quite complicated, since during the reaction a number of derivatives of prothrombin, autoprothrombins and, finally, various types of thrombin (thrombin C, thrombin E) are formed, which have procoagulant, anticoagulant and fibrinolytic activity. The resulting thrombin C - the main product of the reaction - contributes to the coagulation of fibrinogen.

Tissue thromboplastin (factor III)

Tissue thromboplastin is a thermostable lipoprotein found in various organs - in the lungs, brain, kidneys, heart, liver, skeletal muscles. The tissues do not contain it in an active state, but in the form of a precursor - prothromboplastin. Tissue thromboplastin, when interacting with plasma factors (VII, IV), is able to activate factor X, participates in the external pathway for the formation of prothrombinase, a complex of factors that convert to thrombin.

Calcium ions (factor IV)

Calcium ions are involved in all three phases of blood coagulation: in the activation of prothrombinase (phase I), the conversion of prothrombin into thrombin (phase II) and fibrinogen into fibrin (phase III). Calcium is able to bind heparin, thereby accelerating blood clotting. In the absence of calcium, platelet aggregation and retraction of the blood clot are impaired. Calcium ions inhibit fibrinolysis.

Proaccelerin (factor V)

Proaccelerin (factor V, plasma AC-globulin or labile factor) is formed in the liver, but, unlike other hepatic factors of the prothrombin complex (II, VII, and X), does not depend on vitamin K. It is easily destroyed. The content of factor V in plasma - 12 - 17 units / ml (about 0.01 g / l), half-life - 15 - 18 hours. The minimum level required for hemostasis is 10-15%.

Proaccelerin is necessary for the formation of internal (blood) prothrombinase (activates factor X) and for the conversion of prothrombin to thrombin.

Accelerin (factor VI)

Accelerin (factor VI or serum AC-globulin) is the active form of factor V. Excluded from the nomenclature of coagulation factors, only the inactive form of the enzyme is recognized - factor V (proaccelerin), which, when traces of thrombin appear, becomes active.

Proconvertin, convertin (factor VII)

Proconvertin is synthesized in the liver with the participation of vitamin K. It remains in stabilized blood for a long time, and is activated by a wetted surface. The content of factor VII in plasma is about 0.005 g / l, the half-life is 4 - 6 hours. The minimum level required for hemostasis is 5-10%.

Convertin, the active form of the factor, plays a major role in the formation of tissue prothrombinase and in the conversion of prothrombin to thrombin. Activation of factor VII occurs at the very beginning of the chain reaction upon contact with a foreign surface. During the clotting process, proconvertin is not consumed and is stored in the serum.

Antihemophilic globulin A (factor VIII)

Antihemophilic globulin A is produced in the liver, spleen, endothelial cells, leukocytes, and kidneys. The content of factor VIII in plasma is 0.01 - 0.02 g / l, the half-life is 7 - 8 hours. The minimum level required for hemostasis is 30-35%.

Antihemophilic globulin A is involved in the "internal" pathway for the formation of prothrombinase, enhancing the activating effect of factor IXa (activated factor IX) on factor X. Factor VIII circulates in the blood, being associated with.

Antihemophilic globulin B (Christmas factor, factor IX)

Antihemophilic globulin B (Christmas factor, factor IX) is formed in the liver with the participation of vitamin K, is thermostable, and remains in plasma and serum for a long time. The content of factor IX in plasma is about 0.003 g/l. The half-life is 7-8 hours. The minimum level required for hemostasis is 20-30%.

Antihemophilic globulin B is involved in the "internal" pathway of prothrombinase formation, activating factor X in combination with factor VIII, calcium ions and platelet factor 3.

Stuart-Prower Factor (Factor X)

Stuart-Prower factor is produced in the liver in an inactive state, activated by trypsin and an enzyme from viper venom. K-vitamin-dependent, relatively stable, half-life - 30 - 70 hours. The content of factor X in plasma is about 0.01 g / l. The minimum level required for hemostasis is 10-20%.

The Stuart-Prower factor (factor X) is involved in the formation of prothrombinase. In the modern blood coagulation scheme, active factor X (Xa) is the central factor in prothrombinase, which converts prothrombin to thrombin. Factor X is converted into the active form under the influence of factors VII and III (external, tissue, prothrombinase formation pathway) or factor IXa together with VIIIa and phospholipid with the participation of calcium ions (internal, blood, prothrombinase formation pathway).

Plasma thromboplastin precursor (factor XI)

The plasma thromboplastin precursor (factor XI, Rosenthal factor, antihemophilic factor C) is synthesized in the liver and is thermolabile. The content of factor XI in plasma is about 0.005 g / l, the half-life is 30 - 70 hours.

The active form of this factor (XIa) is formed with the participation of factors XIIa, and. Form XIa activates factor IX, which is converted to factor IXa.

Hageman Factor (Factor XII, Contact Factor)

Hageman factor (factor XII, contact factor) is synthesized in the liver, produced in an inactive state, the half-life is 50-70 hours. The content of the factor in plasma is about 0.03 g/L. Bleeding does not occur even with very deep factor deficiency (less than 1%).

It is activated upon contact with the surface of quartz, glass, cellite, asbestos, barium carbonate, and in the body - upon contact with the skin, collagen fibers, chondroitin sulfuric acid, micelles of saturated fatty acids. Factor XII activators are also Fletcher's factor, kallikrein, factor XIa, plasmin.

The Hageman factor is involved in the "internal" pathway of prothrombinase formation by activating factor XI.

Fibrin stabilizing factor (factor XIII, fibrinase, plasma transglutaminase)

Fibrin-stabilizing factor (factor XIII, fibrinase, plasma transglutaminase) is determined in the vascular wall, platelets, erythrocytes, kidneys, lungs, muscles, placenta. In plasma, it is in the form of a proenzyme combined with fibrinogen. The active form is converted under the influence of thrombin. It is contained in plasma in an amount of 0.01 - 0.02 g / l, the half-life is 72 hours. The minimum level required for hemostasis is 2-5%.

Fibrin-stabilizing factor is involved in the formation of a dense clot. It also influences the adhesion and aggregation of platelets.

Willebrand factor (antihemorrhagic vascular factor)

The von Willebrand factor (antihemorrhagic vascular factor) is synthesized by the vascular endothelium and megakaryocytes, and is found in plasma and platelets.

The von Willebrand factor serves as an intravascular carrier protein for factor VIII. The binding of von Willebrand factor to factor VIII stabilizes the latter molecule, increases its half-life inside the vessel, and promotes its transport to the site of injury. Another physiological role of the relationship between factor VIII and von Willebrand factor is the ability of von Willebrand factor to increase the concentration of factor VIII at the site of vessel injury. Since circulating von Willebrand factor binds to both exposed subendothelial tissues and stimulated platelets, it directs factor VIII to the affected area, where the latter is required for factor X activation with the participation of factor IXa.

Fletcher factor (plasma prekallikrein)

Fletcher factor (plasma prekallikrein) is synthesized in the liver. The content of the factor in plasma is about 0.05 g/L. Bleeding does not occur even with very deep factor deficiency (less than 1%).

Participates in the activation of factors XII and IX, plasminogen, converts kininogen to kinin.

Fitzgerald factor (plasma kininogen, Flojek factor, Williams factor)

Fitzgerald factor (plasma kininogen, Flojek factor, Williams factor) is synthesized in the liver. The content of the factor in plasma is about 0.06 g/L. Bleeding does not occur even with very deep factor deficiency (less than 1%).

Participates in the activation of factor XII and plasminogen.

Literature:

• Handbook of Clinical Laboratory Research Methods. Ed. E. A. Kost. Moscow, "Medicine", 1975
• Barkagan Z. S. Hemorrhagic diseases and syndromes. - Moscow: Medicine, 1988
• Gritsyuk A. I., Amosova E. N., Gritsyuk I. A. Practical hemostasiology. - Kyiv: Health, 1994
• Shiffman F. J. Blood Pathophysiology. Translation from English - Moscow - St. Petersburg: "Publishing house BINOM" - "Nevsky Dialect", 2000
• Handbook "Laboratory research methods in the clinic", ed. prof. V. V. Menshikov. Moscow, "Medicine", 1987
• Study of the blood system in clinical practice. Ed. G. I. Kozints and V. A. Makarov. - Moscow: Triada-X, 1997